EKSO BIONICS HOLDINGS, INC.EKSO
| Mar 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
---|
Revenue | - | - | - | - | - | 11 | 14 | 9 | 11 | 13 | 18 |
---|
Cost of revenue | - | 4 | 7 | 11 | 5 | 7 | 7 | 4 | 4 | 7 | 9 |
---|
Gross profit | - | 2 | 1 | 3 | 2 | 4 | 7 | 5 | 7 | 6 | 9 |
---|
Sales and marketing | - | 7 | 9 | 11 | 13 | 14 | 11 | 8 | 7 | 7 | 8 |
---|
Sales and marketing | - | 7 | 9 | 11 | 13 | 14 | 11 | 8 | 7 | 7 | 8 |
---|
Research and development | - | 4 | 6 | 9 | 9 | 6 | 5 | 2 | 3 | 4 | 5 |
---|
Research and development | - | 4 | 6 | 9 | 9 | 6 | 5 | 2 | 3 | 4 | 5 |
---|
General and administrative | - | 7 | 7 | 11 | 11 | 12 | 7 | 8 | 11 | 11 | 11 |
---|
General and administrative | - | 7 | 7 | 11 | 11 | 12 | 7 | 8 | 11 | 11 | 11 |
---|
Total operating expenses | - | 18 | 23 | 31 | 34 | 31 | 23 | 18 | 21 | 22 | 24 |
---|
Total operating expenses | - | 18 | 23 | 31 | 34 | 31 | 23 | 18 | 21 | 22 | 24 |
---|
Loss from operations | - | -17 | -22 | -28 | -32 | -27 | -17 | -13 | -14 | -16 | -15 |
---|
Interest expense, net | - | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
---|
(Loss) gain on revaluation of warrant liabilities | - | - | - | - | - | - | - | - | - | - | -0 |
---|
Unrealized gain (loss) on foreign exchange | - | - | - | - | 1 | -0 | -0 | 1 | -1 | -1 | 0 |
---|
Other expense, net | - | -17 | 2 | 4 | 0 | -0 | -0 | 1 | -1 | -0 | -0 |
---|
Total other (expense) income, net | - | -0 | -0 | -0 | 2 | 0 | 5 | -3 | 4 | 0 | -0 |
---|
Net loss | -12,292 | -34 | -20 | -23 | -29 | -27 | -12 | -16 | -10 | -15 | -15 |
---|
Foreign currency translation adjustments | - | - | - | 0 | -0 | 0 | 0 | -1 | 1 | 1 | -0 |
---|
Comprehensive loss | - | - | - | -34 | -30 | -27 | -12 | -17 | -9 | -14 | -16 |
---|
Net loss per share applicable to common shareholders, basic and diluted (in dollars per share) | - | - | -0.24 | -1.87 | -0.82 | - | - | - | -0.8 | -1.16 | -1.1 |
---|
Revenue | - | - | - | - | - | 11 | 14 | 9 | 11 | 13 | 18 |
---|
Cost of revenue | - | 4 | 7 | 11 | 5 | 7 | 7 | 4 | 4 | 7 | 9 |
---|
Gross profit | - | 2 | 1 | 3 | 2 | 4 | 7 | 5 | 7 | 6 | 9 |
---|
Sales and marketing | - | 7 | 9 | 11 | 13 | 14 | 11 | 8 | 7 | 7 | 8 |
---|
Sales and marketing | - | 7 | 9 | 11 | 13 | 14 | 11 | 8 | 7 | 7 | 8 |
---|
Research and development | - | 4 | 6 | 9 | 9 | 6 | 5 | 2 | 3 | 4 | 5 |
---|
Research and development | - | 4 | 6 | 9 | 9 | 6 | 5 | 2 | 3 | 4 | 5 |
---|
General and administrative | - | 7 | 7 | 11 | 11 | 12 | 7 | 8 | 11 | 11 | 11 |
---|
General and administrative | - | 7 | 7 | 11 | 11 | 12 | 7 | 8 | 11 | 11 | 11 |
---|
Total operating expenses | - | 18 | 23 | 31 | 34 | 31 | 23 | 18 | 21 | 22 | 24 |
---|
Total operating expenses | - | 18 | 23 | 31 | 34 | 31 | 23 | 18 | 21 | 22 | 24 |
---|
Loss from operations | - | -17 | -22 | -28 | -32 | -27 | -17 | -13 | -14 | -16 | -15 |
---|
Loss from operations | - | -17 | -22 | -28 | -32 | -27 | -17 | -13 | -14 | -16 | -15 |
---|
Interest expense, net | - | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
---|
Gain (Loss) On Warrant Liability | - | - | - | 4 | 4 | 1 | 6 | -3 | 4 | 1 | - |
---|
Gain on forgiveness of note payable | - | - | - | - | - | - | -0 | - | 1 | - | - |
---|
Unrealized loss on foreign exchange | - | - | - | - | 1 | -0 | -0 | 1 | -1 | -1 | 0 |
---|
Other expense, net | - | -17 | 2 | 4 | 0 | -0 | -0 | 1 | -1 | -0 | -0 |
---|
Total other (expense) income, net | - | -0 | -0 | -0 | 2 | 0 | 5 | -3 | 4 | 0 | -0 |
---|
Net loss | -12,292 | -34 | -20 | -23 | -29 | -27 | -12 | -16 | -10 | -15 | -15 |
---|
Foreign currency translation adjustments | - | - | - | 0 | -0 | 0 | 0 | -1 | 1 | 1 | -0 |
---|
Comprehensive loss | - | - | - | -34 | -30 | -27 | -12 | -17 | -9 | -14 | -16 |
---|
Basic net loss per share applicable to common shareholders (in dollars per share) | - | - | -0.24 | -1.87 | -0.82 | - | - | - | -0.8 | -1.16 | -1.1 |
---|
Earnings Per Share, Diluted | - | - | -0.26 | -2.05 | -0.82 | - | - | - | -0.88 | -1.16 | - |
---|